Dyadic International's fair value estimate has held steady at $5.67 per share, even as the discount rate has risen slightly from 7.04% to 7.20%. This adjustment reflects a blend of optimism about ...

JUPITER, FL / ACCESSWIRE / July 15, 2020 / Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a global biotechnology company ...

Access to ERS Genomics’ foundational CRISPR/Cas9 patent portfolio expands our genetic engineering toolkit and strengthens our ability to speed up and optimize strain development across Dyadic’s ...

Webcast Link: https://viavid.webcasts.com/starthere.jsp?ei=1650831&tp_key=0f89478e24. An archive of the webcast will be available within 24 hours after completion of ...

Dyadic management will be available during these events for one-on-one meetings. Interested parties may request a one-on-one meeting at [email protected] or contact Dyadic at (561) 743-8333. About ...

The latest announcement is out from Dyadic International ( (DYAI)). Dyadic International has secured a $3 million grant from the Bill & Melinda Gates Foundation to develop cost-effective monoclonal ...

The average one-year price target for Dyadic International (NasdaqCM:DYAI) has been revised to $5.78 / share. This is a ...

Dyadic’s management team welcomes the opportunity to connect with investors, analysts, and industry partners during the conferences. To request a meeting, please reach out to [email protected].

JUPITER, FL / ACCESSWIRE / January 11, 2021 / Dyadic International, Inc. ("Dyadic") (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene ...

Webcast Link: https://viavid.webcasts.com/starthere.jsp?ei=1705993&tp_key=2267a6328b. An archive of the webcast will be available within 24 hours after completion of ...